EXPRESS: A long-term field safety study evaluating allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis (FCGS).

Allogeneic UMSCs demonstrate long-term safety and clinical efficacy for refractory feline gingivostomatitis with sustained improvement.

This prospective, multi-site, open-label extension study evaluated the long-term safety and effectiveness of allogeneic uterine-derived mesenchymal stromal cells (UMSCs) in 35 client-owned cats with refractory feline chronic gingivostomatitis (FCGS) that persisted despite extraction and medical management. Cats received two intravenous doses of 20 million UMSCs 14 days apart during the initial trial, with follow-up extending to Day 365. Safety assessment revealed no serious adverse events or clinically relevant abnormalities in hematology or urinalysis. Transient gastrointestinal and respiratory signs were the most common AEs. Clinical efficacy showed 69% of cats gained weight (mean 16.2%), with owner-reported improvement of 75.8% at Day 180 and 65.6% at Day 365. Veterinarian-assessed global oral lesion scores improved 51.5% and 46.9% at corresponding timepoints, with 22% achieving clinical cure. Notably, 66% of cats discontinued medical therapy post-UMSC treatment, with only 8.6% continuing immunosuppressants. These findings support UMSC therapy as a safe long-term treatment for refractory FCGS with meaningful quality-of-life improvements.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.